Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors
Science Advances · 2025
DOI: 10.1126/sciadv.adw5228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von William Yang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc, Mitochondria, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
MYC is a key driver in many aggressive and therapy-resistant cancers. We have developed and characterized a small-molecule MYC inhibitor named MYCi975. To uncover combination strategies for MYC inhibitors, we conducted a genome-wide CRISPR screen using MYCi975. This screen revealed a notable synthetic lethality when MYC inhibition was paired with disruption of mitochondrial complex I components, but not other complexes. Mechanistically, MYC inhibition reduced oxidative phosphorylation and glycolysis, triggering a compensatory up-regulation of complex I genes. Consequently, genetic or pharmacological targeting of complex I sensitized tumors to MYCi975 treatment, leading to increased purine catabolism and infiltration of CD8 + T cells and macrophages into tumors. Additionally, a wide range of tumor cells with lower complex I expression showed increased MYC dependency. These results indicate that metabolic adaptation to MYC inhibition exposes a targetable weakness at complex I and provide a rational strategy for combination therapy with emerging MYC inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Division of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA.
- Department of Chemistry, Northwestern University, Evanston, IL, USA.
ORCID-Profile: William Yang, Songhua Quan, Zachary R Chalmers, Mihai Truica, Megan M Kerber, Dikshat G Gupta, Adam W T Steffeck, Hao Pan, H Tran Pham, Gary E Schiltz, Debabrata Chakravarti, Navdeep S Chandel, Sarki A Abdulkadir
Förderung
- NCI NIH HHS
Zitieren
APA
Yang, W., Guo, Q., Quan, S., Chalmers, Z. R., Parker, J. B., Truica, M., Dufficy, M. F., Kerber, M. M., Vasan, K., Gupta, D. G., Steffeck, A. W. T., Pan, H., Siddiqui, M., Pham, H. T., Schiltz, G. E., Chakravarti, D., Chandel, N. S., & Abdulkadir, S. A. (2025). Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science Advances. https://doi.org/10.1126/sciadv.adw5228
Vancouver
Yang W, Guo Q, Quan S, Chalmers ZR, Parker JB, Truica M, et al. Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science Advances. 2025. doi:10.1126/sciadv.adw5228
BibTeX
@article{Yang2025,
author = {Yang, William and Guo, Qianyu and Quan, Songhua and Chalmers, Zachary R and Parker, J Brandon and Truica, Mihai and Dufficy, Mary F and Kerber, Megan M and Vasan, Karthik and Gupta, Dikshat G and Steffeck, Adam W T and Pan, Hao and Siddiqui, Mohammed and Pham, H Tran and Schiltz, Gary E and Chakravarti, Debabrata and Chandel, Navdeep S and Abdulkadir, Sarki A},
title = {Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adw5228}
}
EUVIMED